

REMARKS

The requisite fee of \$1852.00 for payment of the Issue Fee for a large entity (\$1510), publication fee (\$300) and an advance order of 14 copies of the issued patent (\$42), and any other fees that may be due in connection with this paper or this application during its entire pendency, should be charged to Deposit Account No. 02-1818. If a Petition for extension of time is needed, this paper is to be considered such Petition.

Supplemental Information Disclosure Statement

Pursuant to the Request of the Examiner, provided herein is a copy of a supplemental Information Disclosure Statement that was mailed April 9, 2009. Receipt of the Supplemental Disclosure Statement was acknowledged by the Office as evidenced by the date stamp on the first page, indicating the date of April 9, 2009. The Supplemental Information Disclosure Statement included a copy of an Office Action that issued in a related case, and a Table with a box for the Examiner to initial that the Examiner considered the Office Action. The Supplemental Information Statement was mis-coded in the system as a Transmittal Letter. Applicant's representative contacted Examiner Balasubramania, who requested that a copy of the Table be included with the Issue Fee. Examiner Balasubramania indicated that he would initial the table evidencing consideration of the Office Action from the related case.

Amendment of the Claims

Claims 1, 4-8 and 10-19 are allowed. Upon review of the claims in preparation of payment of the issue fee, it has been determined that claims 1, 4, 7, 8, 10, 16, 18 and 19 contain inadvertant errors, which are addressed by the amendments herein. Claim 1 is amended to correct grammatical errors by replacing the recitation "A compound of the formula I" with "A compound of formula I" and to amend the definition of substituent G by replacing the recitation "from the group of" with the recitation "from among." Claims 1 and 15 are amended to correct an inadvertant typographical error in the definition of substituent R¹³, by replacing the recitation SO₂NR₁₅NR₁₅' with the recitation SO₂NR₁₅R₁₅'. Basis for this amendment is found in claim 1 as originally filed. Claim 4 is amended to include the recitation "X is NR₄." Basis for this amendment is found in original claim 4.

Claims 4, 7 and 8 are amended to replace the recitation "or a pharmaceutically acceptable salt *thereof*" with the recitation "or a pharmaceutically acceptable salt of claim 1" for proper dependency of the claims. Claims 4, 7 and 8 each ultimately depend from claim 1,

Applicant : Hamann *et al.*
Serial No. : 10/712,456
Filed : November 13, 2003

Attorney Docket No. 3800024.00560 / 4207
Amendment Pursuant to 37 C.F.R. §1.312

which recites "or a pharmaceutically acceptable salt *thereof*." Thus, claim 1 is directed to a compound of formula I or a pharmaceutically acceptable salt of a compound of formula I. Therefore, claims 4, 7 and 8 should recite "or a pharmaceutically acceptable salt of claim 1" for proper dependency.

Claim 10 is amended to correct a typographical error by inserting an omitted parenthesis in the second recited compound. Claim 10 is amended by replacing the recitation "1-(4-Cyanonaphthalen-1-ylcarbamoyl-3-hydroxy-pyrrolidine-2-carboxylic" with the recitation "1-(4-Cyanonaphthalen-1-ylcarbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic."

Claims 16, 18 and 19 are amended to replace the recitation "or a pharmaceutically acceptable salt *thereof*" with the recitation "or a pharmaceutically acceptable salt of claim 15" for proper dependency of the claims. Claims 16, 18 and 19 each ultimately depend from claim 15, which recites "or a pharmaceutically acceptable salt *thereof*." Thus, claim 15 is directed to a compound of formula I or a pharmaceutically acceptable salt of a compound of formula I. Therefore, claims 16, 18 and 19 should recite "or a pharmaceutically acceptable salt of claim 15" for proper dependency. No new matter is added. Accordingly, entry of this amendment respectfully is requested.

* * *

Entry of these remarks and the amendment into the file history of the above-captioned application respectfully is requested.

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 3800024.00560 / 4207
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, CA 92130-6766
Telephone: (858) 509-7400
Facsimile: (858) 509-7466
email: stephanie.seidman@klgates.com